Patients with Human epidermal growth factor receptor 2 (HER2)-overexpressed gastric adenocarcinoma are recommended to receive pembrolizumab in combination with trastuzumab and chemotherapy (fluoropyrimidine and platinum) as first-line therapy. Here, ERBB2 is linked to gastric adenocarcinoma.